GAIN THERAPEUTICS, INC Marketable Securities (Current)
GAIN THERAPEUTICS, INC (GANX) had Marketable Securities (Current) of $2.02 million as of 2024-03-31, per its 10-Q filed 2024-05-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2025-03-27
- 2024-03-31: Marketable Securities, Current $2.02M.
- 2023-12-31: Marketable Securities, Current $5.00M.
- 2023-09-30: Marketable Securities, Current $7.96M.
- 2023-06-30: Marketable Securities, Current $9.87M.
| Period end | Marketable Securities, Current |
|---|---|
| 2024-03-31 | $2.02M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $5.00M 10-K · filed 2025-03-27 |
| 2023-09-30 | $7.96M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $9.87M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $11.83M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $12.83M 10-K · filed 2024-03-26 |
| 2022-09-30 | $11.85M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $9.94M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |